CytomX Therapeutics Inc
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic w… Read more
Market Cap & Net Worth: CytomX Therapeutics Inc (CTMX)
CytomX Therapeutics Inc (NASDAQ:CTMX) has a market capitalization of $923.42 Million ($923.42 Million) as of March 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #8643 globally and #4319 in its home market, demonstrating a 8.35% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying CytomX Therapeutics Inc's stock price $5.45 by its total outstanding shares 169435395 (169.44 Million).
CytomX Therapeutics Inc Market Cap History: 2015 to 2026
CytomX Therapeutics Inc's market capitalization history from 2015 to 2026. Data shows change from $3.54 Billion to $923.42 Million (-6.40% CAGR).
Index Memberships
CytomX Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.03% | #242 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.00% | #932 of 3165 |
Weight: CytomX Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
CytomX Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how CytomX Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.26x
CytomX Therapeutics Inc's market cap is 1.26 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
5.48x
CytomX Therapeutics Inc's market cap is 5.48 times its annual earnings
0.11x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $3.54 Billion | $7.71 Million | -$35.37 Million | 458.52x | N/A |
| 2016 | $1.86 Billion | $15.04 Million | -$58.90 Million | 123.78x | N/A |
| 2017 | $3.58 Billion | $71.62 Million | -$43.10 Million | 49.94x | N/A |
| 2018 | $2.56 Billion | $59.50 Million | -$84.60 Million | 43.00x | N/A |
| 2019 | $1.41 Billion | $57.49 Million | -$102.24 Million | 24.49x | N/A |
| 2020 | $1.11 Billion | $68.43 Million | -$64.82 Million | 16.22x | N/A |
| 2021 | $733.66 Million | $69.57 Million | -$80.65 Million | 10.55x | N/A |
| 2022 | $271.10 Million | $53.16 Million | -$97.30 Million | 5.10x | N/A |
| 2023 | $262.62 Million | $101.21 Million | -$569.00K | 2.59x | N/A |
| 2024 | $174.52 Million | $138.10 Million | $31.87 Million | 1.26x | 5.48x |
Competitor Companies of CTMX by Market Capitalization
Companies near CytomX Therapeutics Inc in the global market cap rankings as of March 18, 2026.
Key companies related to CytomX Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
CytomX Therapeutics Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, CytomX Therapeutics Inc's market cap moved from $3.54 Billion to $ 923.42 Million, with a yearly change of -6.40%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $923.42 Million | +27.93% |
| 2025 | $721.79 Million | +313.59% |
| 2024 | $174.52 Million | -33.55% |
| 2023 | $262.62 Million | -3.12% |
| 2022 | $271.10 Million | -63.05% |
| 2021 | $733.66 Million | -33.89% |
| 2020 | $1.11 Billion | -21.18% |
| 2019 | $1.41 Billion | -44.97% |
| 2018 | $2.56 Billion | -28.47% |
| 2017 | $3.58 Billion | +92.08% |
| 2016 | $1.86 Billion | -47.34% |
| 2015 | $3.54 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of CytomX Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $923.42 Million USD |
| MoneyControl | $923.42 Million USD |
| MarketWatch | $923.42 Million USD |
| marketcap.company | $923.42 Million USD |
| Reuters | $923.42 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.